All In Biotech

NDA 215425 · Fresenius Kabi USA

Epinephrine

Epinephrine · Intramuscular, Intravenous, Subcutaneous · alpha-Adrenergic Agonist; beta-Adrenergic Agonist; Catecholamine

Last checked: Nov 19, 2026Latest source record: Mar 13, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2025

Mar 13, 2025

Approved uses

1

Original approval plus efficacy supplements

Registered trials

2,347

454 Phase 3, 232 recruiting

FAERS reports

42,335

26,333 serious, 3,545 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 15, 2026.

Epinephrine is a non-selective alpha and beta adrenergic agonist indicated: • For emergency treatment of allergic reactions (Type 1), including anaphylaxis, in adults and pediatric patients. ( 1.1 ) • To increase mean arterial blood pressure in adult patients with hypotension associated with septic shock. ( 1.2 ) 1.1 Anaphylaxis Epinephrine Injection is indicated for emergency treatment of type I allergic reactions, including anaphylaxis, in adults and pediatric patients. 1.2 Hypotension associated with Septic Shock Epinephrine Injection is indicated to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock.

Mechanism: Anaphylaxis Epinephrine acts on both alpha- and beta-adrenergic receptors. Through its action on alpha-adrenergic receptors, epinephrine lessens the vasodilation and increased vascular permeability that occurs during anaphylaxis, which can lead to loss of intravascular fluid volume and hypotension. Through its action on beta-adrenergic receptors, epinephrine causes bronchial smooth muscle relaxation and helps alleviate bronchospasm, wheezing and dyspnea that may occur during anaphylaxis. Epinephrine also alleviates pruritus, urticaria, and angioedema. It may also relieve gastrointestinal and...

Therapeutic areas: Kidney and urology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 13, 2025 Original approval · Type 5 - New Formulation or New Manufacturer LabelLetter
1 products under this application
  • EPINEPHRINE · EPINEPHRINE 30MG/30ML (1MG/ML) · SOLUTION, INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Epinephrine" as an intervention, any sponsor and status, largest first.

All 2,347 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective4,536
  • headache3,074
  • sinusitis2,919
  • fatigue2,801
  • product dose omission issue2,780
  • pain2,488
  • covid-192,424
  • dyspnoea2,269
  • nausea2,230
  • pneumonia2,076
  • off label use2,065
  • inappropriate schedule of product administration1,785

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004133
2005118
2006136
2007166
2008194
2009269
2010261
2011702
2012425
2013301
2014411
2015635
20161,057
20171,572
20182,477
20193,337
20206,460
20213,909
20223,582
20233,781
20244,431
20254,735
20263,240

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Epinephrine (Epinephrine)

2024 spending

$119M

Beneficiaries

458,644

578,447 claims

Per beneficiary

$260

$99.63 per unit

View as table
YearSpending
2020$94,680,100
2021$121,105,229
2022$116,328,376
2023$133,365,359
2024$119,280,229

Part B: Epinephrine (Epinephrine HCL/PF) · HCPCS J0173

2024 spending

$28K

Beneficiaries

1,177

1,251 claims

Per beneficiary

$24

2024 ASP limit $1.89 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$0
2024$28,242

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 4,529 on PubMed

Sponsor: Fresenius Kabi USA

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.